JMIRx Med first overlay journal accepted for PubMed and PubMed Central

“MIR Publications is proud to announce that our first-of-its-kind overlay journal, JMIRx Med, has been accepted for indexing in PubMed Central (PMC) and PubMed.

As the first overlay journal in PMC and PubMed, JMIRx Med becomes the standard-bearer of this important innovation in scholarly publishing. Editors of overlay journals select content already posted on preprint servers such as medRxiv and bioRxiv. They then select manuscripts that match the scope and quality parameters of their publications and offer authors a rapid peer review and possible publication of their preprints, coupled with all the traditional elements of a journal publication. JMIRx Med enters the ranks of PubMed-ranked scientific publications following the US National Library of Medicine’s (NLM’s) rigorous evaluation criteria. Papers published in JMIRx Med will be in PubMed by mid-summer 2022, after legacy files are prepared and deposited….”

Public Access in PMC Update

In 2021, PubMed Central (PMC) continued to grow and evolve in its role as a repository for research support by the National Institutes of Health (NIH) and other partner funding agencies. Around 1.3 million articles have been made publicly accessible in PMC under the NIH Public Access Policy; and the volume of NIH-supported articles added to PMC with associated data content continues to increase annually (59% of articles in 2020 included supplementary material and/or a data availability statement vs. 27% in 2009).

Blog – Europe PMC: Europe PMC adopts the Principles of Open Scholarly Infrastructure

“As a long-standing service and infrastructure provider in the open science ecosystem, Europe PMC supports the Principles of Open Scholarly Infrastructure (POSI). We welcome the momentum gathering behind this initiative to promote the need to support and sustain the open infrastructure.

Europe PMC has been a part of the public and open infrastructure for over 15 years and is run and managed by EMBL-EBI (which is part of the pan-European organisation of EMBL). It is funded by 34 international funders and is community-driven, open infrastructure, set in the context of key global open data resources such as the European Nucleotide Archive (INSDC), the wwPDB and the European Genome-Phenome Archive. All of these resources exist for the public good, led by scientific need and international collaborations, and have open governance structures and a commitment to long-term sustainability. Together with PMC USA, Europe PMC is a part of the PubMed Central International archive network, which plays an integral part in fulfilling shared goals to enable international open science. Europe PMC has been selected as an ELIXIR Core Data Resource, which means that it is of fundamental importance to the wider life-science community and the long-term preservation of biological data….”

Updated PMC Launching Soon!

In the coming weeks, we will be launching an updated PMC website with a modern design. You can try the updated version on PMC Labs now, and it will become the default design of the PMC website following launch. Be sure to check the banner at the top of the PMC website for updates on an exact cutover date.

Updated PMC Launching Soon!

In the coming weeks, we will be launching an updated PMC website with a modern design. You can try the updated version on PMC Labs now, and it will become the default design of the PMC website following launch. Be sure to check the banner at the top of the PMC website for updates on an exact cutover date.

Funders – About – Europe PMC

“Europe PMC has 33 research funders, across Europe. The Europe PMC funders expect:

Research outputs arising from research that we fund to be made freely and readily available;
Electronic copies of any biomedical research papers that have been accepted for publication in a peer-reviewed journal, and are supported in whole or in part by funding from any of the Europe PMC Funders, to be made available through PubMed Central (PMC) and Europe PMC, as soon as possible and in any event within six months of the journal publisher’s official date of final publication;
Authors and publishers, if an open access fee has been paid, to license research papers such that they may be freely copied and re-used for purposes such as text and data mining, provided that such uses are fully attributed. This is also encouraged where no fee has been paid….”

Blog – Europe PMC: Transparency for preprints: handling withdrawals and removals

“Part of the appeal of preprints is the ability to post new versions, allowing researchers to continuously improve their manuscript and correct it if needed. However, in some cases the data or its interpretation presented in the preprint may be proven incorrect with time. In such cases the authors may wish to withdraw or remove the preprint, rather than posting another version. There could also be instances where preprints are removed for legal reasons, due to authorship disputes, or even as a result of erroneous posting. 

Currently, there are several different ways in which preprint platforms handle such scenarios. In the case of a withdrawal the preprint itself is often still accessible, but it is supplemented with a new version containing a withdrawal notice, which explains that the preprint should not be considered part of the scientific record. This is akin to retractions for peer reviewed journal articles. On the other hand, in the case of a removal all preprint versions are removed and the content is no longer accessible, in some cases with a removal notice replacing the preprint itself. You can see the list of different withdrawal/removal policies in the ASAPbio Preprint Server Directory.

For an archive, such as Europe PMC, it is crucial to follow best practices for handling preprint metadata to enable transparency and build trust in preprints. As a proof-of-concept we now provide a way to search and display withdrawn and removed preprints with appropriate labels for the COVID-19 full text preprint subset. We identify preprint withdrawal or removal notices based on document length (notices are often just a single sentence long) using the Europe PMC plus submission system. Those records are then flagged, manually checked and tagged with the appropriate withdrawal or removal article-type [Hamelers A, Parkin M. A full text collection of COVID-19 preprints in Europe PMC using JATS XML]….”

NIH-Wide Strategic Plan: Fiscal Years 2021-2025

“NIH is committed to making findings from the research that it funds accessible and available in a timely manner, while also providing safeguards for privacy, intellectual property, security, and data management. For instance, NIH-funded investigators are expected to make the results and accomplishments of their activities freely available within 12 months of publication. NIH also encourages investigators to share results prior to peer review, such as through preprints, to speed the dissemination of their findings and enhance the rigor of their work through informal peer review. A robust culture of data sharing is critical to continued progress in science, maximizing NIH’s investment in research, and assurance of the highest levels of transparency and rigor. To this end, NIH will continue to promote opportunities for data management and sharing while allowing flexibility for various data types, sharing platforms, and strategies. Additionally, NIH is implementing a policy requiring that all applications include data sharing and management plans that consider input from stakeholders….”

NIH Preprint Pilot Update. NLM Technical Bulletin. 2021 Mar–Apr

“Ten months into the NIH Preprint Pilot, more than 2,100 preprints reporting NIH-supported research on COVID-19 are now discoverable in PubMed Central (PMC) and PubMed. Through early April 2021, these records have been viewed more than 1 million times in each of these databases (1.4 million in PMC; 1 million in PubMed). Of the preprints included in the pilot, ~60% are currently discoverable only as a preprint version, having not yet been linked to a published article. All articles are clearly identified as preprints. Preprints may be selected or excluded in searches by using the preprint filter.

The pilot launched in June 2020 with preprint records from medRxiv, bioRxiv, arXiv, ChemRxiv, Research Square, and SSRN. Phase 1 has focused on improving the discoverability of preprints relating to the ongoing public health emergency and accelerating dissemination of NIH-supported research on the SARS-CoV-2 virus and COVID-19. This narrowly scoped first phase has allowed the National Library of Medicine (NLM) to streamline curation and ingest workflows for NIH-supported preprints and refine the details of implementation with a set of articles for which there has been high demand for accelerated access and discovery. Since launching the pilot, NLM has made display of preprint records in PubMed search results more transparent. We have also automated checks for new preprint versions and preprint withdrawals, and reduced the steps required to report preprints as products of awards in My Bibliography….”

Max Planck Society, Rockefeller University Press Enter “Read-and-Publish” Transformative Agreement

“Max Planck Digital Library (MPDL) has signed an unlimited “read-and-publish” transformative agreement with Rockefeller University Press (RUP) on behalf of the Max Planck Society. The agreement covers Open Access (OA) publishing of articles in RUP’s three hybrid journals: Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM) and Journal of General Physiology (JGP).

Under the agreement, which runs from January 1, 2021 to December 31, 2022,  articles by corresponding authors affiliated with Max Planck Institutes will be published immediate open access under a CC-BY license and directly deposited in PubMed Central (PMC). The transformative agreement repurposes former subscription funds to cover all open access publishing fees for authors, and there is no limit to the number of articles that may be published under the terms of the agreement. Max Planck Institutes also receive unlimited access to RUP’s journals. Learn how authors can take advantage of new agreement….”

Scholarly publishing and journal targeting in the time of the Coronavirus Disease 2019 (COVID-19) pandemic: a cross-sectional survey of rheumatologists and other specialists | SpringerLink

Abstract:  The evolving research landscape in the time of the Coronavirus disease 2019 (COVID-19) pandemic calls for greater understanding of the perceptions of scholars regarding the current state and future of publishing. An anonymised and validated e-survey featuring 30 questions was circulated among rheumatologists and other specialists over social media to understand preferences while choosing target journals, publishing standards, commercial editing services, preprint archiving, social media and alternative publication activities. Of 108 respondents, a significant proportion were clinicians (68%), researchers (60%) and educators (47%), with median 23 publications and 15 peer-review accomplishments. The respondents were mainly rheumatologists from India, Ukraine and Turkey. While choosing target journals, relevance to their field (69%), PubMed Central archiving (61%) and free publishing (59%) were the major factors. Thirty-nine surveyees (36%) claimed that they often targeted local journals for publishing their research. However, only 18 (17%) perceived their local society journals as trustworthy. Occasional publication in the so-called predatory journals (5, 5%) was reported and obtaining support from commercial editing agencies to improve English and data presentation was not uncommon (23, 21%). The opinion on preprint archiving was disputed; only one-third believed preprints were useful. High-quality peer review (56%), full and immediate open access (46%) and post-publication social media promotion (32%) were identified as key anticipated features of scholarly publishing in the foreseeable future. These perceptions of surveyed scholars call for greater access to free publishing, attention to proper usage of English and editing skills, and a larger role for engagement over social media.


Blog – Europe PMC: Announcing the new version of SciLite – the Europe PMC tool for highlighting annotations

“This month, Europe PMC released a new version of SciLite, a powerful tool for highlighting annotations in life sciences publications. SciLite is powered by the Europe PMC annotation platform via the open annotation API, which provides access to over 1.3 billion annotations. Highlighting annotations in the text enables users to easily scan the article and locate key biological entities, such as genes/proteins, accession numbers, protein interactions, diseases, gene-disease relationship and more….”

Europe PMC: unlocking the potential of COVID-19 preprints | European Bioinformatics Institute


Europe PMC is now indexing full-text preprints related to the COVID-19 pandemic and the SARS-CoV-2 virus, as well as the underlying data
The project will make COVID-19 scientific literature available as fast as possible in a single repository, in a format that allows text mining
Researchers and healthcare professionals will be able to access and reuse preprints more easily, accelerating research into better treatments or a vaccine….”